Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:2152 |
Name | ovary epithelial cancer |
Definition | An ovarian cancer that is derives_from ovarian surface epithelium. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Ramucirumab | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | Bevacizumab + Niraparib | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | Bevacizumab + Carboplatin + Paclitaxel | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | Binimetinib + Paclitaxel | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | Afuresertib + Carboplatin + Paclitaxel | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | Alpelisib + Olaparib | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | Dalantercept | ovary epithelial cancer | no benefit | detail... |
Unknown unknown | Niraparib | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | MGD013 | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | Carboplatin + Gemcitabine + Ralimetinib | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | SC-003 | ovary epithelial cancer | no benefit | detail... |
Unknown unknown | Carboplatin + Idronoxil | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | Idronoxil + Paclitaxel | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | Gemcitabine + Idronoxil | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | Docetaxel + Idronoxil | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | Idronoxil | ovary epithelial cancer | not applicable | detail... |
Unknown unknown | CRLX101 + Paclitaxel | ovary epithelial cancer | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00703105 | Phase II | Denileukin diftitox | Ovarian Dendritic Cell Vaccine Trial | Unknown status | USA | 0 |
NCT01012817 | Phase Ib/II | Topotecan + Veliparib | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT01116648 | Phase Ib/II | Olaparib Cediranib + Olaparib | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT01145430 | Phase I | Pegylated liposomal-doxorubicin + Veliparib | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | Completed | USA | 0 |
NCT01146795 | Phase II | Bevacizumab + Carboplatin + Paclitaxel | Neoadjuvant Therapy for Ovarian Cancer | Completed | USA | 0 |
NCT01239732 | Phase III | Bevacizumab + Carboplatin + Paclitaxel | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | Completed | CAN | 36 |
NCT01482715 | Phase Ib/II | Rucaparib | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | Completed | USA | CAN | 3 |
NCT01519869 | Phase I | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | Completed | USA | 0 | |
NCT01535157 | Phase Ib/II | Ketoconazole Fenretinide | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | Terminated | USA | 0 |
NCT01536743 | Phase II | Palbociclib | A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression | Completed | USA | 0 |
NCT01649336 | Phase I | Binimetinib + Paclitaxel | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | Completed | USA | 0 |
NCT01690468 | Phase Ib/II | Carboplatin + Triciribine | PTX-200 and Carboplatin in Ovarian Cancer | Terminated | USA | 0 |
NCT01749397 | Phase I | Floxuridine + Veliparib | Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer | Completed | USA | 0 |
NCT01846611 | Phase III | Pegylated liposomal-doxorubicin Dexamethasone | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Completed | USA | 9 |
NCT01853644 | Phase II | Tivozanib | Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT01891344 | Phase II | Rucaparib | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Active, not recruiting | USA | CAN | 4 |
NCT01968213 | Phase III | Rucaparib | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Active, not recruiting | USA | CAN | 9 |
NCT01991210 | Phase II | DNIB0600A Pegylated liposomal-doxorubicin | A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer | Terminated | USA | CAN | 5 |
NCT02033616 | Phase II | Ovapuldencel-T | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | Recruiting | USA | 0 |
NCT02091999 | Phase I | Enfortumab vedotin-ejfv | A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | Active, not recruiting | USA | CAN | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 3 |
NCT02188550 | Phase II | Everolimus + Letrozole | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | Unknown status | USA | 0 |
NCT02195973 | Phase Ib/II | Paclitaxel + Sonidegib | Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer | Completed | USA | 0 |
NCT02264678 | Phase Ib/II | AZD6738 AZD6738 + Carboplatin AZD6738 + Durvalumab AZD6738 + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | 3 |
NCT02272790 | Phase II | Adavosertib + Pegylated liposomal-doxorubicin Adavosertib + Carboplatin Adavosertib + Gemcitabine Adavosertib + Paclitaxel | Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | CAN | 1 |
NCT02275039 | Phase I | MVAp53 Gemcitabine | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | Completed | USA | 0 |
NCT02278783 | Phase II | Regorafenib | Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Terminated | USA | 0 |
NCT02289950 | Phase II | Farletuzumab | A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer | Completed | USA | 6 |
NCT02354131 | Phase Ib/II | Niraparib Bevacizumab + Niraparib | Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA) | Active, not recruiting | USA | 1 |
NCT02364713 | Phase II | Pegylated liposomal-doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal-doxorubicin Gemcitabine | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | Recruiting | USA | 0 |
NCT02392676 | Phase III | Olaparib | Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations | Withdrawn | USA | 4 |
NCT02534922 | Phase I | Prolanta | Study of Prolanta in Recurrent or Persistent Epithelial Ovarian Cancer (ProlantaOC) | Unknown status | USA | 0 |
NCT02537444 | Phase II | Acalabrutinib Pembrolizumab | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191) | Completed | USA | 0 |
NCT02539719 | Phase I | ABBV-181 + SC-003 SC-003 | Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer | Terminated | USA | 0 |
NCT02540356 | Phase Ib/II | Imalumab | Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer | Terminated | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | 1 |
NCT02644369 | Phase II | Pembrolizumab | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) | Active, not recruiting | CAN | 0 |
NCT02657889 | Phase Ib/II | Niraparib + Pembrolizumab | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO) | Active, not recruiting | USA | 0 |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | 5 |
NCT02674061 | Phase II | Pembrolizumab | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) | Active, not recruiting | 0 | |
NCT02713386 | Phase Ib/II | Ruxolitinib Carboplatin + Paclitaxel | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02718417 | Phase III | Avelumab Carboplatin + Paclitaxel | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | Terminated | USA | CAN | 23 |
NCT02726997 | Phase Ib/II | Carboplatin + Durvalumab + Paclitaxel | Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02728830 | Phase I | Pembrolizumab | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | Active, not recruiting | USA | 0 |
NCT02766582 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | Active, not recruiting | USA | 0 |
NCT02785250 | Phase I | Cyclophosphamide + DPX-Survivac + Epacadostat | Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer | Unknown status | USA | CAN | 0 |
NCT02788708 | Phase I | Lenvatinib + Paclitaxel | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02811497 | Phase II | Azacitidine + Durvalumab | Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) | Active, not recruiting | CAN | 0 |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | 5 |
NCT02833506 | Phase I | NY-ESO-1 peptide vaccine + Sirolimus NY-ESO-1 peptide vaccine | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |
NCT02834975 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | Recruiting | USA | 0 |
NCT02853318 | Phase II | Bevacizumab + Cyclophosphamide + Pembrolizumab | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02855944 | Phase III | Cisplatin Rucaparib Carboplatin Gemcitabine Paclitaxel | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Active, not recruiting | USA | CAN | 10 |
NCT02865811 | Phase II | Pegylated liposomal-doxorubicin + Pembrolizumab | Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02873962 | Phase II | Bevacizumab + Nivolumab | A Phase II Study Of Nivolumab/ Bevacizumab | Recruiting | USA | 0 |
NCT02884648 | Phase II | Bevacizumab | Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery | Recruiting | USA | 0 |
NCT02900560 | Phase II | Azacitidine + Pembrolizumab | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02901899 | Phase II | Guadecitabine + Pembrolizumab | Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT02915523 | Phase Ib/II | Avelumab Avelumab + Entinostat | Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer | Unknown status | USA | 0 |
NCT02922764 | Phase I | RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma | Recruiting | USA | 0 |
NCT02923739 | Phase II | Bevacizumab + Emactuzumab + Paclitaxel Bevacizumab + Paclitaxel | Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT | Active, not recruiting | USA | 0 |
NCT02943317 | Phase I | Defactinib Avelumab | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | Terminated | USA | 0 |
NCT02948101 | Phase II | Cyclophosphamide + PD 0360324 | Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer | Withdrawn | USA | 0 |
NCT02948426 | Phase I | Interferon gamma + Peginterferon alfa-2b | Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Recruiting | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Recruiting | USA | 1 |
NCT03038100 | Phase III | Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050) | Active, not recruiting | USA | 21 |
NCT03054909 | Phase I | ALT-803 | QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer | Suspended | USA | 0 |
NCT03078400 | Phase I | SPL-108 | Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT03079687 | Expanded access | Olaparib | Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Approved for marketing | USA | 0 |
NCT03081702 | Phase Ib/II | Hydroxychloroquine + Itraconazole | A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer | Active, not recruiting | CAN | 0 |
NCT03093155 | Phase II | Bevacizumab + Ixabepilone Ixabepilone | Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab | Active, not recruiting | USA | 0 |
NCT03106987 | Phase III | Olaparib | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (OReO) | Recruiting | CAN | 10 |
NCT03113487 | Phase II | MVAp53 + Pembrolizumab | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Recruiting | USA | 0 |
NCT03138408 | Phase I | SC-004 ABBV-181 + SC-004 | SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers | Terminated | USA | 0 |
NCT03162562 | Phase I | Oregovomab + Poly ICLC | The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | Terminated | USA | 0 |
NCT03206047 | Phase Ib/II | Atezolizumab + Guadecitabine Atezolizumab Atezolizumab + Guadecitabine + Rasdegafusp alfa | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT03206645 | Phase I | Carboplatin + Paclitaxel + PTC596 | PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy | Recruiting | USA | 0 |
NCT03213964 | Phase I | Aldesleukin + FATE-NK100 | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int | Active, not recruiting | USA | 0 |
NCT03245892 | Phase I | Carboplatin + Nivolumab + Paclitaxel | A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer | Recruiting | USA | 0 |
NCT03246074 | Phase I | Fostamatinib + Paclitaxel | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | Recruiting | USA | 0 |
NCT03287271 | Phase Ib/II | Defactinib | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | Recruiting | USA | 0 |
NCT03312114 | Phase II | Avelumab | Anti—PD-L1 and SAbR for Ovarian Cancer | Terminated | USA | 0 |
NCT03318900 | Phase I | Aldesleukin + Cyclophosphamide + Utomilumab | T Cell Immunotherapy for Advanced Ovarian Cancer | Recruiting | USA | 0 |
NCT03319628 | Phase I | XMT-1536 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Recruiting | USA | CAN | 1 |
NCT03326193 | Phase II | Bevacizumab + Niraparib | Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | Active, not recruiting | USA | 0 |
NCT03394885 | Phase Ib/II | Atezolizumab + Carboplatin + Paclitaxel | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (AdORN) | Active, not recruiting | USA | 0 |
NCT03398655 | Phase III | Paclitaxel Paclitaxel + VB-111 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL) | Recruiting | USA | 3 |
NCT03430518 | Phase I | Durvalumab + Eribulin | Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | Completed | USA | 0 |
NCT03519178 | Phase II | PF-06873600 | A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy | Recruiting | USA | 0 |
NCT03522246 | Phase III | Rucaparib Nivolumab Nivolumab + Rucaparib | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) | Active, not recruiting | USA | CAN | 19 |
NCT03558139 | Phase I | Avelumab + Hu5F9-G4 | A Trial of Hu5F9-G4 With Avelumab in Ovarian Cancer | Completed | USA | 0 |
NCT03564340 | Phase Ib/II | Cemiplimab + REGN4018 REGN4018 | Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer | Recruiting | USA | 1 |
NCT03574779 | Phase II | Bevacizumab + Dostarlimab + Niraparib | Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer (OPAL) | Active, not recruiting | USA | 0 |
NCT03579316 | Phase II | Olaparib Adavosertib + Olaparib | Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Recruiting | USA | 0 |
NCT03607955 | Phase I | AVB-S6-500 + Carboplatin + Paclitaxel | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | Not yet recruiting | USA | 0 |
NCT03637764 | Phase Ib/II | Atezolizumab + Isatuximab Isatuximab | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | Active, not recruiting | USA | CAN | 8 |
NCT03642132 | Phase III | Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Talazoparib Avelumab + Carboplatin + Paclitaxel + Talazoparib | Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) | Active, not recruiting | USA | 9 |
NCT03657043 | Phase II | Tisotumab Vedotin | A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208) | Recruiting | USA | 3 |
NCT03691376 | Phase I | Melphalan NY-ESO-1 TCR CD4- CD34+ HSC Aldesleukin Autologous NY-ESO-1-specific CD8-positive T cells | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Recruiting | USA | 0 |
NCT03704467 | Phase II | Bevacizumab + Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin Avelumab + Berzosertib + Carboplatin | Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine Diphosphate Ribose [ADP]-Ribose) Polymerase Inhibitor (PARPi)-Resistant Recurrent Ovarian Cancer | Completed | USA | 2 |
NCT03732950 | Phase II | Pembrolizumab | Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer | Recruiting | USA | 0 |
NCT03734692 | Phase Ib/II | Cisplatin + Pembrolizumab + Rintatolimod | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | Recruiting | USA | 0 |
NCT03735589 | Phase Ib/II | alphaDC1 + NK-like CTLs | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Not yet recruiting | USA | 0 |
NCT03740165 | Phase III | Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Olaparib + Paclitaxel + Pembrolizumab Carboplatin + Olaparib + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43) | Recruiting | USA | CAN | 20 |
NCT03748186 | Phase I | STRO-002 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolR?) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | Recruiting | USA | 0 |
NCT03756818 | Phase I | Mivavotinib + Paclitaxel | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03784677 | Phase I | SOR-C13 | SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors | Recruiting | USA | 0 |
NCT03824704 | Phase II | Nivolumab + Rucaparib | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | Terminated | USA | 0 |
NCT03836352 | Phase II | DPX-Survivac + Pembrolizumab Cyclophosphamide + DPX-Survivac + Pembrolizumab | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | Recruiting | USA | CAN | 0 |
NCT03861403 | Phase Ib/II | Avelumab + Cyclophosphamide + TRX518 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03872206 | Phase Ib/II | HPN536 | Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression | Recruiting | USA | 0 |
NCT03934814 | Phase I | TJ011133 Pembrolizumab + TJ011133 Rituximab + TJ011133 | Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | Recruiting | USA | 1 |
NCT03943173 | Phase I | Olaparib | Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | Recruiting | USA | 0 |
NCT04019288 | Phase Ib/II | AVB-S6-500 + Durvalumab | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Recruiting | USA | 0 |
NCT04024878 | Phase I | NeoVax + Nivolumab | NeoVax With Nivolumab in Patients With Ovarian Cancer | Recruiting | USA | 0 |
NCT04055649 | Phase II | ONC201 + Paclitaxel | ONC201 and Paclitaxel in Treating Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Not yet recruiting | USA | 0 |
NCT04092270 | Phase I | MSC2490484A + Pegylated liposomal-doxorubicin | A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients | Recruiting | USA | 0 |
NCT04122625 | Phase Ib/II | Debio 1143 + Nivolumab | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) | Recruiting | USA | 2 |
NCT04152499 | Phase Ib/II | SKB264 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Recruiting | USA | 1 |
NCT04182516 | Phase I | NMS-03305293 | Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT04239014 | Phase II | Olaparib AZD6738 + Olaparib | A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. (DUETTE) | Withdrawn | USA | CAN | 2 |
NCT04267939 | Phase I | BAY1895344 + Niraparib | ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer | Recruiting | USA | 0 |
NCT04300556 | Phase Ib/II | MORAb-202 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR alpha)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Recruiting | USA | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04469764 | Phase II | Abemaciclib + Anastrozole Abemaciclib + Letrozole Abemaciclib | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | Recruiting | USA | 0 |
NCT04482309 | Phase II | Trastuzumab deruxtecan | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) | Recruiting | USA | CAN | 11 |
NCT04493619 | Phase Ib/II | Carboplatin + PLX2853 PLX2853 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | Recruiting | USA | CAN | 0 |
NCT04498520 | Phase I | Abexinostat + Fulvestrant + Palbociclib | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | Not yet recruiting | USA | 0 |
NCT04516447 | Phase I | Pegylated liposomal-doxorubicin + ZN-c3 Carboplatin + ZN-c3 | A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer | Recruiting | USA | 6 |
NCT04553133 | Phase II | PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 | PF-07104091 as a Single Agent and in Combination Therapy | Recruiting | USA | 0 |
NCT04561817 | Phase II | Ipatasertib + Paclitaxel | To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer | Withdrawn | USA | 0 |
NCT04570839 | Phase Ib/II | BMS-986207 + COM701 + Nivolumab Nivolumab | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | Recruiting | USA | 0 |
NCT04590326 | Phase Ib/II | REGN4018 + REGN5668 Cemiplimab + REGN5668 | Study of REGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer. | Recruiting | USA | 0 |
NCT04598321 | Phase I | Talazoparib | BrUOG 390: Neoadjuvant Treatment With Talazoparib | Not yet recruiting | USA | 0 |
NCT04726332 | Phase I | Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT04753216 | Phase II | Bevacizumab + MM-398 | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Not yet recruiting | USA | 0 |